Investment report on Novavax

MicroStockProfit.com announces an investment report featuring Novavax Inc. (Nasdaq:NVAX).  The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/NVAX

Novavax Inc. (NVAX) is a clinical-stage biopharmaceutical company focused on creating vaccines that improve upon preventive options for a range of infectious diseases.  These vaccines leverage its virus-like particle (VLP) platform technology coupled with a disposable production technology.  The Company's product targets include vaccines against the H5N1 and other subtypes of avian influenza with pandemic potential, human seasonal influenza, Varicella Zoster, which causes shingles, and respiratory syncytial virus (RSV).  The Company also has a joint venture with Cadila Pharmaceuticals Ltd. to develop and commercialize seasonal influenza virus-like-particle-based vaccine candidates and therapeutic vaccine candidates against cancer, as well as adjuvants, biogeneric products and other diagnostic products for the territory of India.  It also has a strategic collaboration with Xcellerex Inc. for the production of 2009 H1N1 influenza vaccine

Message Board Search for NVAX: http://www.boardcentral.com/boards/NVAX

In the report, the analyst notes:

"NVAX reported a net loss of $11.4 million, or $0.11 per share, for the first quarter of 2010 compared to a net loss of $8.3 million, or $0.12 per share, for the first quarter of 2009.  The primary reason for the increased loss for the first quarter of 2010 as compared to the same period in 2009 was due to higher research and development spending to support the Company's clinical trials related to its seasonal and H1N1 influenza vaccine candidates.  

"CPL Biologicals, a joint venture of Cadila Pharmaceuticals Ltd. and NVAX, recently announced that it has completed construction of its vaccine facility in Dholka, India, and will commence equipment and installation validation this month so that the facility conforms to global standards for production of vaccines for human use."